Featured News
Alternative Options for Endocrine Disruptor Testing
Endocrine Disruptor Testing Options Expanded
Since the EFSA & ECHA guidance for endocrine disruptor testing came into effect in 2018, agrochemical and biocide manufacturers have been navigating the need for robust thyroid data in the absence of validated assays. Charles River has now implemented five in vitro tests to assess the effects of a test substance on thyroid hormone signaling pathways, to support the biocide and pesticide active substance approvals process for the agrochemical industry.
Charles River is participating in the EU-NETVAL project validating one of 17 in vitro thyroid assays covered in the project. EU-NETVAL supports validation studies to assess alternative methods that could replace, reduce, or refine the use of animals for scientific purposes. The validation project is due to complete in October 2022.
Ongoing Developments in Endocrine Disruptor Testing
With high profile discussions ongoing around thyroid adversity and its potential neurotoxicological impact, pressure has been high on agrochemical and biocide manufacturers further complicating the initial registration or renewal of biocides and pesticides.
Future-Proof Your Endocrine Disruptor Strategy Under REACH
View this webinar to explore endocrine disruptor testing under REACH, real-life testing solution examples.
Watch now
With anticipated changes to REACH regulations in relation to endocrine disruptor testing due in the coming year, industrial chemical manufacturers could also benefit from these newly available assays to screen classes and potential substances in their costly development pipeline to remove potentially hazardous substances. Within Charles River, scientific and regulatory colleagues work together to ensure the best testing strategy for your portfolio preventing additional costs and time.
In Vitro Thyroid Assays Completing Data Gaps
"We see clients who have adversity data from their in vivo studies and until now the challenge has been to produce mechanistic data from in vitro studies. We can now provide in vitro thyroid assays to show that this adversity data is not in fact related to thyroid and therefore endocrine disruption.
With these new assays, Charles River now offers end to end endocrine disruptor testing solutions so clients don’t need to go between testing partners. Clients can rely on our experience and expertise to guide them through, what can often be, a complicated testing process to get their product to market or keep it there."
Mira Wenker, Head of the Endocrine Expert Team at Charles River
Charles River’s newly available in vitro thyroid assays are as follows:
- Thyroid receptor binding and transactivation (TRβ-CALUX® assay)
- Thyroid peroxidase (TPO) inhibition
- Iodine uptake (NIS assay)
- Transthyrethin (TTR)-binding
- In vitro and ex vivo T3 and/or T4 glucuronidation (UDPGT induction assay)
For more information on our solutions for endocrine disruptor testing speak to our expert team.